Antibacterial compounds and biological applications thereof

1. The compounds having the general formula (I)

wherein,

A 1 and A 2 , identical or different, are H, (C 1 -C 6 )alkyl, (C 1 -C 6 )fluoroalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 1 -C 6 )alkyl-OR a , (C 1 -C 6 )alkyl-SR a , (C 1 -C 6 )alkyl-NR a R b , OR a , SR a , NR a R b , or COR a ;

A 3 is H, OH or form a carbonyl with A 4 ;

A 4 is H, OH or form a carbonyl with A 3 ;

A 5 is H, CR a R b OH, F, OH or forms a double bond with X in the case where X is CH;

A 6 is H or F;

X is CH 2 , CHF, CF 2 , CHOH, O, or a simple bond, or X is CH in the case where A 5 forms with X a double bond;

Y is P(O)(OR a )(OR b ) or P(O)(OR a )(NR a R b );

V is O;

A 7 is H, (C 1 -C 6 )alkyl, (C 1 -C 6 )fluoroalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl or (C 1 -C 6 )alkyl-OR a ;

As is OH or H;

R a and R b , identical or different, are selected from the group consisting of H, (C 1 -C 6 )alkyl, (C 1 -C 6 )fluoroalkyl, (C 1 -C 6 )alkyl-OH and (C 1 -C 6 )alkyl-O—(C 1 -C 6 )alkyl; in the form of pure diastereoisomers and mixtures of diastereoisomers, as well as the cyclic hemiketal or cyclic hemiacetal forms for compounds bearing carbonyl and hydroxyl groups, and their addition salts thereof with acids and bases.

2. The compounds of formula (I) and their addition salts thereof with acids and bases, according to claim 1 , wherein Y is P(O)(OH) 2 .

3. The compounds of general formula (I) and pharmaceutically acceptable addition salts thereof with acids and bases as defined in claim 2 , for use as drugs.

4. The compounds of formula (I) and their addition salts thereof with acids and bases, according to claim 1 , wherein X is CH 2 , CHF, CF 2 , CHOH or O.

5. The compounds of formula (I) and their addition salts thereof with acids and bases, according to claim 1 , wherein A 1 and A 2 are H or one of them is H and the other is (C 1 -C 6 )alkyl or one of them is H and the other is fluoro(C 1 -C 6 )alkyl or one of them is H and the other is (C 1 -C 6 )alkyl-OR a or one of them is H and the other is (C 1 -C 6 )alkyl-SR a or one of them is H and the other is COR a , R a being as defined in claim 1 , or one of them is H and the other is OH.

6. The compounds of formula (I) and their addition salts thereof with acids and bases, according to claim 1 , wherein when A 3 forms a carbonyl with A 4 , As is OH or CR a R b OH, R a and R b being as defined in claim 1 , and when A 3 doesn't form a carbonyl with A 4 , As is H or F.

7. The compounds of formula (I) and their addition salts thereof with acids and bases, according to claim 1 , wherein A 7 is H or (C 1 -C 6 )alkyl.

8. The compounds of formula (I) according to claim 1 which names follow:

N-hydroxy-N-formylamino-1-deoxy-D-ribitol-5-phosphate, [6-(Formyl-hydroxy-amino)-(3R,4R,5S)-3,4,5-trihydroxy-hexyl]-phosphonic acid, [[6-(Formyl-hydroxy-amino)-(3R,4R,5S)-1,3,4,5-tetra-hydroxy-hexyl]-phosphonic acid, [(2S,3S,4S)-5-(Formyl-hydroxy-amino)-2,3,4-trihydroxy-pentyl]-phosphonic acid (1-(N-benzyloxy-N-formylamino)-1,5-dideoxy-D-ribitol] 5-phosphonic acid), 1-(N-benzyloxy-N-formylamino)-1-deoxy-5,6-dihydroxy-D-ribo-hexitol)]-6-phosphonic acid, [(3R,4R,5S)-6-(Formyl-hydroxy-amino)-3,4,5,7-tetrahydroxy-heptyl]-phosphonic acid (diastereoisomers DIA1 and DIA2), [1-Fluoro-6-(formyl-hydroxy-amino)-(3R,4R,5S)-3,4,5-trihydroxy-hexyl]-phosphonic acid, (3R,4S,5R)-3,4,5-trihydroxy-6-(N-hydroxyformamido) hexyl)phosphonic acid, (3R,4R,5R)-3,4,5-trihydroxy-6-(N-hydroxyformamido)-hexylphosphonic acid, [1,1-Difluoro-6-(formyl-hydroxy-amino)-(3R,4R,5S)-3,4,5-trihydroxy-hexyl]-phosphonic acid, [1-(N-hydroxy-N-formylamino)-1,6-dideoxy-D-allo/L-talo-hexitol)] 6-phosphonic acid, 1-(N-benzyloxy-N-formylamino)-1-deoxy-D-ribo-5-(E)-hexenitol 6-phosphonic acid and their addition salts thereof with acids and bases, in particular their sodium salts.

9. The compounds of general formula (I) and pharmaceutically acceptable addition salts thereof with acids and bases, as defined in claim 8 , for use as drugs.

10. The compounds of general formula (I) and pharmaceutically acceptable addition salts thereof with acids and bases as defined in claim 1 , for use as drugs.

11. The compounds of general formula (I) and pharmaceutically acceptable addition salts thereof with acids and bases as defined in claim 1 for use as drugs for the therapeutical treatment of infections due to Gram-negative bacteria in human or animals.

12. The compounds of general formula (I) and pharmaceutically acceptable addition salts thereof with acids and bases, as defined in claim 1 , for use as drugs in combination with an antibacterial, an antivirulence agent, a drug reinforcing the host innate immunity or a combination of any of them.

13. The compounds of general formula (I) and pharmaceutically acceptable addition salts thereof with acids and bases, as defined in claim 1 , for use as drugs in combination with macrolides, streptogramins, pleuromutilins, FabI inhibitors, rifamycins, lipopeptides, GM-CSF or a combination of any of them.

14. Pharmaceutical compositions containing as active principle a compound of general formula (I) or a pharmaceutically acceptable addition salt thereof with an acid or a base, as defined in claim 1 .

15. Mixture or pharmaceutical association comprising as active principles a compound of formula (I) or a pharmaceutically acceptable addition salt thereof with an acid or a base, as defined in claim 1 , and an antibacterial, an antivirulence agent, a drug reinforcing the host innate immunity or a combination of any of them.

16. Mixture or pharmaceutical association comprising as active principles a compound of formula (I) or a pharmaceutically acceptable addition salt thereof with an acid or a base, as defined in claim 1 , and a macrolide, a streptogramin, a pleuromutilin, a FabI inhibitor, a rifamycin, a lipopeptide, a GM-CSF or a combination of any of them.